GT719 Injection Clinical Trials
5 recruitingBiologic
Early Phase 13Phase 12Phase 21
Showing 1–5 of 5 trials
Recruiting
Early Phase 1
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
Auto Immune Disease
Grit Biotechnology30 enrolled1 locationNCT07132112
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
Hematological Malignancy (Leukemia- Lymphoma)
Grit Biotechnology34 enrolled1 locationNCT07131254
Recruiting
Early Phase 1
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Autoimmune Diseases
Grit Biotechnology10 enrolled1 locationNCT07122076
Recruiting
Phase 1Phase 2
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Hematological Malignancy (Leukemia- Lymphoma)
Grit Biotechnology46 enrolled1 locationNCT06948981
Recruiting
Phase 1
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Neurological Autoimmune Diseases
Grit Biotechnology30 enrolled1 locationNCT07021209